Abstract
Objective: Recent studies have shown that distal-less homeobox 6 antisense 1 (DLX6-AS1) is aberrantly expressed in various cancers and is associated with poor prognosis. This meta-analysis is designed to investigate the effects of DLX6-AS1 expression on clinicopathological features and survival outcomes. Methods: All eligible studies were searched from Pubmed, Web of Science, Embase, the Cochrane Library, and Wanfang database, up to August 2019. The literature was selected according to the inclusion and exclusion criteria listed in this work, and the quality of each eligible study was assessed. Each patient’s clinicopathological features and survival data were analyzed using Stata12.0 software. Begg’s test and sensitivity analysis were also conducted. Results: A total of 12 articles were included, covering 841 patients. Results showed that high expression of DLX6-AS1 was significantly closely associated with poor overall survival in tumor patients (hazard ratio (HR) = 2.30, confidence interval (95% CI): 1.70–3.09, P<0.01). This meta-analysis also showed that overexpression of DLX6-AS1 was significantly associated with tumor stage (P<0.01), tumor size (P<0.01), lymph node metastasis (P<0.01), and distant metastasis (P<0.01). Begg’s test suggested no publication bias. Conclusion: This meta-analysis revealed that high expression of DLX6-AS1 was related to the advanced clinicopathological characteristics of human digestive system cancers (gastric cancer, esophageal cancer, colon cancer, pancreatic cancer, and hepatocellular carcinoma) and other cancers such as ovarian cancer, osteosarcoma and non-small cell lung cancer, and DLX6-AS1 has important predictive value for poor prognosis. However, more studies are needed to further corroborate these findings.
Highlights
Cancer is an important public health problem worldwide, and it is the leading cause of deaths in China
An increasing number of studies have shown that long-chain non-coding RNA (lncRNA) is abnormally expressed in many human cancers, and it plays an important role in the initiation and progression of cancer
[2], SNHG1 [3], DANCR [4], and HOTAIR [5] are related to the clinicopathological features and prognosis of tumors. These findings demonstrate that lncRNA may be a tumor-specific prognostic biomarker and therapeutic target [6]
Summary
Cancer is an important public health problem worldwide, and it is the leading cause of deaths in China. The development of cancer involves the ectopic movement, deletion, and expansion of chromosomes. The diagnosis and treatment of cancer have made great progress in recent years, the prognosis of cancer patients is still very poor. There is still a dearth of markers for early diagnosis of cancer and therapeutically effective targets. Most lncRNAs cannot encode proteins, they participate in most cellular and physiological processes by acting as post-transcriptional regulators, enhancers, splicing regulators, and chromosomal modifiers. An increasing number of studies have shown that lncRNA is abnormally expressed in many human cancers, and it plays an important role in the initiation and progression of cancer. Previous meta-analyses have indicated that ZEB1-AS1 [1], MALAT1
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
